IN10018 Combination Therapy in Previously-treated Solid Tumors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a phase Ib/II, randomized, open-label, multicenter clinical trial to evaluate the antitumor activities, safety, tolerability and pharmacokinetics (PK) of IN10018 in combination with taxane and anti-PD-1/L1 monoclonal antibody in patients with locally advanced or metastatic solid tumors who have failed in or been intolerant to at least one line of standard therapy. This study will be firstly carried out in previously-treated non-small cell lung cancer (NSCLC) population,
Epistemonikos ID: 381404bae238d2293f428df89a576260f53fa8b3
First added on: May 15, 2024